|
|
|
| Research progress on ionizing radiation exposure and thyroid cancer |
| JIANG Xinyue, LIU Jienan, GAO Meiling, WANG Yuchao, HONG Yina, YAN Jianbo
|
| Zhoushan Center for Disease Control and Prevention (Zhoushan Institute of Public Health Supervision), Zhoushan, Zhejiang 316021, China |
|
|
|
|
Abstract Thyroid cancer is caused by multiple factors, including genetics, environment, metabolism, and the immune microenvironment, among which ionizing radiation exposure is an important risk factor for thyroid cancer. As one of the most sensitive target organs of ionizing radiation, the thyroid gland may have different risks of thyroid cancer caused by different types of ionizing radiation exposures, such as medical exposure, occupational exposure, and emergency exposure. The sensitivity of children and adolescents are higher than that of adults. The dose-response relationship still needs to be further explored. The molecular mechanism between ionizing radiation and the increased risk of thyroid cancer is complex, which may involve DNA damage and repair abnormalities, gene mutations, non-coding RNA regulation, DNA methylation, cell cycle regulation imbalance, and immune microenvironment changes. This article reviews the risk and molecular mechanisms associated with different types of ionizing radiation exposure in thyroid cancer, based on literature retrieved from CNKI and PubMed databases. It aims to provide a theoretical basis for the early monitoring, prevention, and intervention of thyroid cancer related to ionizing radiation exposure.
|
|
Received: 12 December 2024
Revised: 20 April 2025
Published: 23 May 2025
|
|
|
|
|
|
[1] BOUCAI L,ZAFEREO M,CABANILLAS M E.Thyroid cancer:a review[J].JAMA,2024,331(5):425-435.
[2] SAENKO V,MITSUTAKE N.Radiation-related thyroid cancer[J].Endocr Rev,2024,45(1):1-29.
[3] The 2007 recommendations of the international commission on radiological protection.ICRP publication 103[J].Ann ICRP,2007,37(2/3/4):1-332.
[4] World Health Organization.Ionizing radiation and health effects[EB/OL].[2025-04-20].https://www.who.int/news-room/fact-sheets/detail/ionizing-radiation-and-health-effects.
[5] DOM G,TARABICHI M,UNGER K,et al.A gene expression signature distinguishes normal tissues of sporadic and radiation-induced papillary thyroid carcinomas[J].Br J Cancer,2012,107(6):994-1000.
[6] 常纯卉,付熙明,陈惠芳,等.碘甲状腺阻滞导则的介绍[J].中国辐射卫生,2021,30(3):253-257,263.
CHANG C H,FU X M,CHEN H F,et al.Introduction of guidelines for iodine thyroid blocking[J].Chin J Radiol Health,2021,30(3):253-257,263.(in Chinese)
[7] CHANG L A,MILLER D L,LEE C,et al.Thyroid radiation dose to patients from diagnostic radiology procedures over eight decades:1930-2010[J].Health Phys,2017,113(6):458-473.
[8] LEE Y K,LEE S,LEE E K,et al.Can computed tomography scanning in adults lead to an increased risk of thyroid cancer? A nationwide nested case-control study[J].Eur Radiol,2022,32(1):415-423.
[9] SHIM S R,KITAHARA C M,CHA E S,et al.Cancer risk after radioactive iodine treatment for hyperthyroidism:a systematic review and meta-analysis[J/OL].JAMA Netw Open,2021,4(9)[2025-04-20].https://doi.org/10.1001/jamanetworkopen.2021.25072.
[10] RICHARDSON D B,CARDIS E,DANIELS R D,et al.Site-specific solid cancer mortality after exposure to ionizing radiation:a cohort study of workers(inworks)[J].Epidemiology,2018,29(1):31-40.
[11] LIU G S,COOK A,RICHARDSON M,et al.Thyroid cancer risk in airline cockpit and cabin crew:a meta-analysis[J].Cancers Head Neck,2018,3:7-14.
[12] 刘小莲,张素芬,郭玮珍,等.广东省医学放射工作人员甲状腺异常情况及影响因素[J].环境与职业医学,2023,40(3):323-330.
LIU X L,ZHANG S F,GUO W Z,et al.Thyroid abnormalities and influencing factors in medical radiology workers in Guangdong Province[J].J Environ Occup Med,2023,40(3):323-330.(in Chinese)
[13] KITAHARA C M,PRESTON D L,NETA G,et al.Occupational radiation exposure and thyroid cancer incidence in a cohort of U.S. radiologic technologists,1983-2013[J].Int J Cancer,2018,143(9):2145-2149.
[14] LEE W J,PRESTON D L,CHA E S,et al.Thyroid cancer risks among medical radiation workers in South Korea,1996-2015[J].Environ Health,2019,18(1):19-28.
[15] FURUKAWA K,PRESTON D,FUNAMOTO S,et al.Long-term trend of thyroid cancer risk among Japanese atomic-bomb survivors:60 years after exposure[J].Int J Cancer,2013,132(5):1222-1226.
[16] CARDIS E,KESMINIENE A,IVANOV V,et al.Risk of thyroid cancer after exposure to 131I in childhood[J].J Natl Cancer Inst,2005,97(10):724-732.
[17] SHIMURA H,SUZUKI S,YOKOYA S,et al.A comprehensive review of the progress and evaluation of the thyroid ultrasound examination program,the Fukushima health management survey[J].J Epidemiol,2022,32(Suppl.XII):23-35.
[18] SHIMURA H,SOBUE T,TAKAHASHI H,et al.Findings of thyroid ultrasound examination within 3 years after the Fukushima nuclear power plant accident:the Fukushima health management survey[J].J Clin Endocrinol Metab,2018,103(3):861-869.
[19] GROELLY F J,FAWKES M,DAGG R A,et al.Targeting DNA damage response pathways in cancer[J].Nat Rev Cancer,2023,23(2):78-94.
[20] 刘涵笑,方连英,李洁清,等.低剂量辐射适应性反应机制研究进展[J].中国辐射卫生,2020,29(4):438-441.
LIU H X,FANG L Y,LI J Q,et al.Advances on the mechanisms of adaptive response to low dose radiation[J].Chin J Radiol Health,2020,29(4):438-441.(in Chinese)
[21] KIRILLOVA E N,LUKYANOVA T V,URYADNITSKAYA T I,et al.Assessment of the status of effector and regulatory components of immune system in Chelyabinsk region residents exposed to radiation due to residence in the area contaminated as a result of the radiation accident at Mayak PA and in their offspring[J].Radiats Biol Radioecol,2017,57(1):42-52.
[22] XING M,WESTRA W H,TUFANO R P,et al.BRAF mutation predicts a poorer clinical prognosis for papillary thyroid cancer[J].J Clin Endocrinol Metab,2005,90(12):6373-6379.
[23] ZHANG Z L,WU Y F,FU J R,et al.Proteostatic reactivation of the developmental transcription factor TBX3 drives BRAF/MAPK-mediated tumorigenesis[J]. Nat Commun,2024,15(1):1-18.
[24] ARIGHI E,BORRELLO M G,SARIOLA H.RET tyrosine kinase signaling in development and cancer[J].Cytokine Growth Factor Rev,2005,16(4/5):441-467.
[25] NIKIFOROV Y E,NIKIFOROVA M N.Molecular genetics and diagnosis of thyroid cancer[J]. Nat Rev Endocrinol,2011,7(10):569-580.
[26] ZHANG Y,ZHENG W H,ZHOU S H,et al.Molecular genetics,therapeutics and RET inhibitor resistance for medullary thyroid carcinoma and future perspectives[J].Cell Commun Signal,2024,22(1):460-486.
[27] BONHOMME B,GODBERT Y,PEROT G,et al.Molecular pathology of anaplastic thyroid carcinomas:a retrospective study of 144 cases[J].Thyroid,2017,27(5):682-692.
[28] ROMEI C,ELISEI R.A narrative review of genetic alterations in primary thyroid epithelial cancer[J].Int J Mol Sci,2021,22(4):1726-1741.
[29] EFANOV A A,BRENNER A V,BOGDANOVA T I,et al.Investigation of the relationship between radiation dose and gene mutations and fusions in post-Chernobyl thyroid cancer[J].J Natl Cancer Inst,2018,110(4):371-378.
[30] LIYANARACHCHI S,GUDMUNDSSON J,FERKINGSTAD E,et al.Assessing thyroid cancer risk using polygenic risk scores[J].Proc Natl Acad Sci U S A,2020,117(11):5997-6002.
[31] FU S B,MA C X,TANG X L,et al.MiR-192-5p inhibits proliferation,migration,and invasion in papillary thyroid carcinoma cells by regulation of SH3RF3[J/OL].Biosci Rep,2021,41(9)[2025-04-20].https://doi.org/10.1042/BSR20210342.
[32] LI L,LIN X Z,XU P,et al.LncRNA GAS5 sponges miR-362-5p to promote sensitivity of thyroid cancer cells to 131I by upregulating SMG1[J].IUBMB Life,2020,72(11):2420-2431.
[33] MYERS A P,CORSON L B,ROSSANT J,et al.Characterization of mouse Rsk4 as an inhibitor of fibroblast growth factor-RAS-extracellular signal-regulated kinase signaling[J].Mol Cell Biol,2004,24(10):4255-4266.
[34] SHAHDUST M,ZARREDAR H,ASADI M,et al.Association of promoter methylation patterns with expression of MAPK14 in tissue of papillary thyroid cancer patients[J].Asian Pac J Cancer Prev,2023,24(10):3509-3515.
[35] NIU H,YANG J Y,YANG K X,et al.The relationship between RASSF1A promoter methylation and thyroid carcinoma:a meta-analysis of 14 articles and a bioinformatics of 2 databases(PRISMA)[J/OL].Medicine(Baltimore),2017,96(46)[2025-04-20].https://doi.org/10.1097/MD.0000000000008630.
[36] 宋婷婷,刘江豪.上调miR-378b抑制ALX4甲基化、抑制甲状腺癌细胞上皮-间质转化、侵袭和迁移[J].解剖科学进展,2024,30(1):90-94.
SONG T T,LIU J H.Up-regulation of miR-378b inhibits epithelial-mesenchymal transition,invasion and migration of thyroid cancer cells by inhibiting ALX4 methylation[J].Prog Anatomi Sci,2024,30(1):90-94.(in Chinese)
[37] GHELLI LUSERNA DI RORA' A,IACOBUCCI I,MARTINELLI G.The cell cycle checkpoint inhibitors in the treatment of leukemias[J].J Hematol Oncol,2017,10(1):77-90.
[38] NICKOLOFF J A,SHARMA N,ALLEN C P,et al.Roles of homologous recombination in response to ionizing radiation-induced DNA damage[J]. Int J Radiat Biol,2023,99(6):903-914.
[39] MORTON L M,KARYADI D M,STEWART C,et al.Radiation-related genomic profile of papillary thyroid carcinoma after the Chernobyl accident[J/OL].Science,2021[2025-04-20].https://doi.org/10.1126/science.abg2538.
[40] YEAGER M,MACHIELA M J,KOTHIYAL P,et al.Lack of transgenerational effects of ionizing radiation exposure from the Chernobyl accident[J].Science,2021,372(6543):725-729.
[41] ZHAO J Y,WEN J,WANG S N,et al.Association between adipokines and thyroid carcinoma:a meta-analysis of case-control studies[J].BMC Cancer,2020,20(1):788-800.
[42] LV N N,LIU F,CHENG L,et al.The expression of transcription factors is different in papillary thyroid cancer cells during TNF-α induced EMT[J].J Cancer,2021,12(9):2777-2786.
[43] ZHANG G Q,JIAO Q,SHEN C T,et al.Interleukin 6 regulates the expression of programmed cell death ligand 1 in thyroid cancer[J].Cancer Sci,2021,112(3):997-1010.
[44] YANG L Y,ZHAO R Y,QIAO P P,et al.The novel oncogenic factor TET3 combines with AHR to promote thyroid cancer lymphangiogenesis via the HIF-1α/VEGF signaling pathway[J].Cancer Cell Int,2023,23(1):206-219.
[45] KOMATSUDA H,KONO M,WAKISAKA R,et al.Harnessing immunity to treat advanced thyroid cancer[J].Vaccines(Basel),2023,12(1):45-61.
[46] BURROWS N,TELFER B,BRABANT G,et al.Inhibiting the phosphatidylinositide 3-kinase pathway blocks radiation-induced metastasis associated with Rho-GTPase and Hypoxia-inducible factor-1 activity[J]. Radiother Oncol,2013,108(3):548-553. |
|
|
|
